美国食品和药物管理局实时监测临床试验数据, 加快药品批准. FDA pilots real-time clinical trial data monitoring to accelerate drug approvals.

美国食品和药物管理局正在启动一个实验计划, 以实时监测临床试验数据, 并旨在加快药品批准. The FDA is launching a pilot program to monitor clinical trial data in real time, aiming to accelerate drug approvals. 该机构将从AstraZeneca和Amgen收到综合安全性和有效性的信号,而无需访问原始患者记录. The agency will receive aggregated safety and efficacy signals from AstraZeneca and Amgen without accessing raw patient records. 通过允许持续监督, 该倡议旨在减少开发延迟, 但安全仍然是首要任务. This initiative seeks to reduce development delays by allowing continuous oversight, though safety remains the top priority.